Want to see VBIO full AI Analyst Report?
Valion Bio (VBIO) Stock Statistics & Valuation Metrics
Total Valuation
Valion Bio has a market cap or net worth of $1.10M. The enterprise value is $24.70M.
- Market Cap
- $1.10M
- Enterprise Value
- $24.70M
Share Statistics
Valion Bio has 2,155,637 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 2,155,637
- Owned by Insiders
- 3.37%
- Owned by Institutions
- 0.15%
Financial Efficiency
Valion Bio’s return on equity (ROE) is -0.53 and return on invested capital (ROIC) is -25.51%.
- Return on Equity (ROE)
- -0.53
- Return on Assets (ROA)
- -0.28
- Return on Invested Capital (ROIC)
- -25.51%
- Return on Capital Employed (ROCE)
- -0.26
- Revenue Per Employee
- 0
- Profits Per Employee
- -170.73K
- Employee Count
- 52
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Valion Bio is -0.00. Valion Bio’s PEG ratio is 0.00.
- PE Ratio
- -0.00
- PS Ratio
- -7.05
- PB Ratio
- 0.01
- Price to FCF
- -0.07
- Price to Operating Cash Flow
- -0.00
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Valion Bio had revenue of 0 and earned -8.88M in profits. Earnings per share was -7.84.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -7.90M
- Pretax Income
- -7.99M
- Net Income
- -8.88M
- EBITDA
- -7.84M
- Earnings Per Share (EPS)
- -7.84
Cash Flow
In the last 12 months, operating cash flow was -14.57M and capital expenditures -99,000, giving a free cash flow of -14.67M billion.
- Operating Cash Flow
- -14.57M
- Free Cash Flow
- -14.67M
- Free Cash Flow per Share
- -108.54
Dividends & Yields
Valion Bio pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1335.02%
- Earnings Yield
- -27198.36%
Stock Price Statistics
- Beta
- 2.46
- 52-Week Price Change
- -99.09%
- 50-Day Moving Average
- 1.91
- 200-Day Moving Average
- 13.87
- Relative Strength Index (RSI)
- 20.04
- Average Volume (3m)
- 1.98M
Important Dates
Valion Bio upcoming earnings date is Nov 13, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 17, 2026
- Next Earnings Date
- Nov 13, 2026
- Ex-Dividend Date
- ―
Financial Position
Valion Bio as a current ratio of 20.13, with Debt / Equity ratio of 38.42%
- Current Ratio
- 20.13
- Quick Ratio
- 20.13
- Debt to Market Cap
- 0.15
- Net Debt to EBITDA
- 0.79
- Interest Coverage Ratio
- -54.10
Taxes
In the past 12 months, Valion Bio has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Valion Bio EV to EBITDA ratio is -1.05, with an EV/FCF ratio of -1.12.
- EV to Sales
- -105.13
- EV to EBITDA
- -1.05
- EV to Free Cash Flow
- -1.12
- EV to Operating Cash Flow
- -1.13
Balance Sheet
Valion Bio has $2.11M in cash and marketable securities with $17.41M in debt, giving a net cash position of -$15.30M billion.
- Cash & Marketable Securities
- $2.11M
- Total Debt
- $17.41M
- Net Cash
- -$15.30M
- Net Cash Per Share
- -$7.10
- Tangible Book Value Per Share
- $45.75
Margins
Gross margin is 516.03%, with operating margin of 10587.18%, and net profit margin of 12019.23%.
- Gross Margin
- 516.03%
- Operating Margin
- 10587.18%
- Pretax Margin
- 11437.18%
- Net Profit Margin
- 12019.23%
- EBITDA Margin
- 9972.44%
- EBIT Margin
- 10480.77%
Scores
- Smart Score
- ―
- AI Score
- 43
